xemilofiban

xem·il·of·i·ban

(zem'il-of'ĭ-ban), An antiplatelet agent that blocks the binding of fibrinogen to specific membrane GPIIb/IIIa integrin receptors and thus prevents platelet aggregation induced by any known platelet agonist.

xemilofiban

A GP IIb/IIIa receptor antagonist or 'superaspirin' oral antiplatelet agent designed to prevent blood clot formation after coronary angioplasty; it was assessed during EXCITE trials to evaluate whether daily postprocedure xemilofiban for 6 months would ↓ clot-related cardiac events in Pts undergoing PCTA and stent placement; xemilofibran was less effective than aspirin and has been abandoned